Drug Trial Radar · NCT07357584
Efficacy and Safety of Doravirine in the Rapid Initiation
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Fundación HuéspedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MSD Pharmaceuticals LLC; Fundacion IDEAA
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."
Conditions
- HIV-1-infection
Interventions
Doravirine / lamivudine/ Tenofovir Disoproxil Oral TabletDrug
Pharmaceutical form: Oral tablets Unit dose concentration/dose level(s): 100/300/245 mg Administration instructions: Take one tablet once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the antiviral activity of DOR/3TC/TDF at week 48 in HIV patients without prior antiretroviral treatment, in a rapid initiation setting.Time frame: 48 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fundacion Huesped
Buenos Aires, Argentina · Recruiting
Fundacion IDEAA -Infectologia de atencion ambulatoria
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.